30/10/2024  19:03:17 Chg. - Volume Bid- Demandez à- Capitalisation boursière Dividende Y. Rapport P/E
17.0000USD - 100
Chiffrre d'affaires: 1,700
-Bid taille: - -Ask la taille: - 11.7 Mrd.USD - -

Description de l'entreprise

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
 

Conseil d'administration & Conseil de surveillance

PDG
Kåre Schultz
Conseil d'administration
Eli Kalif, David M. Stark, Dr. Hafrun Fridriksdottir, Eli Shani, Eric Drapé, Galia Inbar, Lori Queisser, Mark Sabag, Nir Baron, Richard Daniell, Sven Dethlefs
Conseil de surveillance
Dr. Sol J. Barer, Amir Elstein, Dr. Perry D. Nisen, Dr. Tal Zaks, Gerald M. Lieberman, Janet S. Vergis, Jean-Michel Halfon, Kåre Schultz, Nechemia J. Peres, Prof. Ronit Satchi-Fainaro, Roberto A. Mignone, Rosemary A. Crane
 

Données de l'entreprise

Nom: Teva Pharmaceuticals Industries Ltd.
Adresse: 5 Basel St.,Petach Tikva 49131, Israel
Téléphone: +972-3-914-8171
Fax: +972-3-914-8678
Courriel: -
Internet: www.tevapharm.com
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: Pharmaceuticals
Fin de l'exercice financier: 31/12
Flotte libre: 88.20%
IPO date: -

Relations avec les investisseurs

Nom: Kevin C. Mannix
Téléphone IR: +215-591-8912
IR-Fax: -
E-mail IR: kevin.mannix@tevapharm.com

Calendrier de l'entreprise

CW 45 | 06/11/2024 Interim Report 3rd Quarter/9 Months
 

Principaux actionnaires